Lilly soon to bag EU approval for Alzheimer's imaging agent with CHMP thumbs-up
This article was originally published in Clinica
Executive Summary
Six months after receiving US FDA approval, Lilly and Avid Radiopharmaceuticals' Alzheimer's imaging agent Amyvid (florbetapir F 18 injection) is now likely to be approved in the EU after receiving a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP). Formal approval from the European Medicines Agency usually follows within three months of a CHMP positive opinion.